"Experts note that there are no randomized controlled trial data to prove that any of these peptides work. Moreover, experts worry about various safety concerns, including impurities from gray- or black-market products, random dose sizes, as well as combinations of unproven peptides, sometimes called 'stacks.'"
"The data on these peptides is 'just woefully minuscule,' Eric Topol, director of the Scripps Research Translational Institute, told the Times. 'It's a mess, because we don't have any data that these work.'"
The FDA is moving to allow compounding pharmacies to produce 14 peptides currently restricted, amid safety concerns and political criticism. Popular peptides like BPC-157, CJC-1295, and Ipamorelin may be included. Experts highlight the absence of randomized controlled trial data to support the effectiveness of these peptides. Concerns include impurities from unregulated sources, inconsistent dosages, and potential health risks such as cancer and hormonal imbalances. Recent incidents of illness linked to peptide injections underscore the risks involved.
Read at Ars Technica
Unable to calculate read time
Collection
[
|
...
]